Glass-Marmor and colleagues¹ randomised 17 patients with multiple sclerosis in acute relapse to receive intravenous methylprednisolone (MP) in the morning or at night, together with infusion of placebo at the other time point, in an inpatient setting (see page 886). When admitted for a subsequent relapse, those originally treated in the morning had intravenous MP at night, and vice versa. In this way, daytime and …